全文获取类型
收费全文 | 329篇 |
免费 | 52篇 |
国内免费 | 65篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 13篇 |
临床医学 | 48篇 |
内科学 | 243篇 |
皮肤病学 | 2篇 |
神经病学 | 2篇 |
外科学 | 25篇 |
综合类 | 13篇 |
预防医学 | 10篇 |
眼科学 | 1篇 |
药学 | 85篇 |
肿瘤学 | 3篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 10篇 |
2019年 | 17篇 |
2018年 | 28篇 |
2017年 | 12篇 |
2016年 | 19篇 |
2015年 | 19篇 |
2014年 | 14篇 |
2013年 | 16篇 |
2012年 | 15篇 |
2011年 | 15篇 |
2010年 | 10篇 |
2009年 | 8篇 |
2008年 | 16篇 |
2007年 | 53篇 |
2006年 | 9篇 |
2005年 | 22篇 |
2004年 | 13篇 |
2003年 | 7篇 |
2002年 | 10篇 |
2001年 | 18篇 |
2000年 | 12篇 |
1999年 | 15篇 |
1998年 | 13篇 |
1997年 | 5篇 |
1996年 | 7篇 |
1995年 | 4篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1989年 | 5篇 |
1988年 | 1篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1976年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有446条查询结果,搜索用时 31 毫秒
1.
2.
B. Shen MD Z. Younossi MD B. Dolmatch MD J. Newman MD M. Henderson MD J. Ong MD T. Gramlich MD M. Yamani MD 《The American journal of gastroenterology》2000,95(9):2607-2607
3.
4.
5.
6.
7.
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy 总被引:5,自引:0,他引:5
Pockros PJ Shiffman ML Schiff ER Sulkowski MS Younossi Z Dieterich DT Wright TL Mody SH Tang KL Goon BL Bowers PJ Leitz G Afdhal NH;PROACTIVE Study Group 《Hepatology (Baltimore, Md.)》2004,40(6):1450-1458
Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb < or = 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-week double-blind phase (DBP), followed by an 8-week open-label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV-infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy. 相似文献
8.
A new variant of type II von Willebrand disease with aberrant multimeric structure of plasma but not platelet von Willebrand factor (type IIF) 总被引:2,自引:0,他引:2
A patient with a lifelong bleeding disorder was diagnosed as having Type II von Willebrand disease. The larger multimers of von Willebrand factor were absent from her plasma but present in platelets. A high- resolution electrophoretic technique was used to study the complex structure of individual von Willebrand factor multimers. In normal plasma, each multimer could be resolved into five bands: a more intense central one and four less intense, two moving faster and two slower than the central band. In normal platelets, each multimer could also be resolved into five bands. The central one had a mobility similar to that in plasma, whereas the four satellite bands had a mobility that differed from that of the corresponding plasma bands. In the patient, platelet von Willebrand factor antigen content and ristocetin cofactor activity were normal, and von Willebrand factor showed the same structure of individual multimers as seen in normal platelets. On the other hand, plasma von Willebrand factor antigen and ristocetin cofactor activity were decreased, and the structure of individual von Willebrand factor multimers was different from that of normal plasma and similar to that seen in normal and patient's platelets. After infusion of 1-deamino-8-D-arginine vasopressin, the largest von Willebrand factor multimers, as well as new satellite bands with a mobility similar to those in normal plasma, appeared in the patient plasma, and the levels of von Willebrand factor antigen and ristocetin cofactor activity became normal. Yet no relevant change in the prolonged bleeding time was observed. This new variant of von Willebrand disease, therefore, is characterized by the presence of a dysfunctional von Willebrand factor molecule that exhibits unique structural abnormalities in plasma but appears to be normal in platelets. The designation of Type IIF is proposed for this type of von Willebrand disease in accordance with the terminology that has been previously used. 相似文献
9.
10.
Zobair Younossi Maria Stepanova Arun J. Sanyal Stephen A. Harrison Vlad Ratziu Manal F. Abdelmalek Anna Mae Diehl Stephen Caldwell Mitchell L. Shiffman Raul Aguilar Schall Bryan McColgan G. Mani Subramanian Robert P. Myers Andrew Muir Nezam H. Afdhal Jaime Bosch Zachary Goodman 《Journal of hepatology》2018,68(6):1365-1370